Endogenous tissue factor pathway inhibitor has a limited effect on host defence in murine pneumococcal pneumonia

Thrombosis and Haemostasis

Volumn 114, Issue 1, 2015, Pages 115-122

  van den Boogaard, Florry E ^a   van ’t Veer, Cornelis ^a   Roelofs, Joris J T H ^a   Meijers, Joost C M ^a   Schultz, Marcus J ^a   Broze, George ^a   van der Poll, Tom ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bacterial infection; Coagulation inhibitors; Inflammation; Lung; Streptococcus pneumoniae

Indexed keywords

D DIMER; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; THROMBIN ANTITHROMBIN COMPLEX; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL TRANSMISSION; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; GENETIC COMPLEMENTATION; HISTOPATHOLOGY; HOST RESISTANCE; IMMUNE RESPONSE; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; ANIMAL; BLOOD; BLOOD CLOTTING; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; GENETICS; GENOTYPE; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PHENOTYPE; TIME FACTOR;

ANIMALS; BACTERIAL LOAD; BLOOD COAGULATION; CYTOKINES; DISEASE MODELS, ANIMAL; GENOTYPE; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATION MEDIATORS; LIPOPROTEINS; LUNG; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 84934755680     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-12-1053     Document Type: Article

References (50)

1. Jones RN, et al. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents 2010; 36: 197-204.
2. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009; 374: 1543-1556.
3. Bartlett JG, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31: 347-382.
4. Choi G, et al. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 2008; 36: 204-210.
5. Gunther A, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 454-462.
6. Rijneveld AW, et al. Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 2003; 102: 934-939.
7. Rijneveld AW, et al. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 2006; 34: 1725-1730.
8. Levi M, et al. Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med 2003; 31(4 Suppl): S238-S242.
9. Wygrecka M, et al. Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. Thromb Haemost 2008; 99: 494-501.
10. van der Poll T. Tissue factor as an initiator of coagulation and inflammation in the lung. Crit Care 2008; 12 (Suppl 6): S3.
11. Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2008; 28: 233-242.
12. Bastarache JA, et al. Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol 2008; 294: L874-L881.
13. de Moerloose P, et al. Procoagulant activity in bronchoalveolar fluids: no relationship with tissue factor pathway inhibitor activity. Thromb Res 1992; 65: 507-518.
14. El Solh AA, et al. Clinical and hemostatic responses to treatment in ventilatorassociated pneumonia: role of bacterial pathogens. Crit Care Med 2007; 35: 490-496.
15. Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood 2009; 114: 2367-2374.
16. Massberg S, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16: 887-896.
17. Choi G, et al. Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation. Eur Respir J 2007; 30: 423-428.
18. Enkhbaatar P, et al. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide- induced pulmonary vascular injury by inhibiting leukocyte activation. Am J Respir Crit Care Med 2000; 162: 1752-1759.
19. Miller DL, et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 2002; 26: 650-658.
20. van den Boogaard FE, et al. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. J Thromb Haemost 2011; 9: 122-132.
21. Welty-Wolf KE, et al. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 2001; 164: 1988-1996.
22. Wunderink RG, et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2011; 183: 1561-1568.
23. Huang ZF, et al. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997; 90: 944-951.
24. van Zoelen MA, et al. The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol 2009; 182: 4349-4356.
25. van den Boogaard FE, et al. Mast cells impair host defense during murine Streptococcus pneumoniae pneumonia. J Infect Dis 2014; 210: 1376-1384.
26. Schouten M, et al. Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia. J Infect Dis 2010; 202: 1600-1607.
27. Sandset PM, et al. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987; 47: 389-400.
28. Papareddy P, et al. C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules. J Biol Chem 2010; 285: 28387-28398.
29. Schirm S, et al. Fragmented tissue factor pathway inhibitor (TFPI) and TFPI C-terminal peptides eliminate serum-resistant Escherichia coli from blood cultures. J Infect Dis 2009; 199: 1807-1815.
30. Camerota AJ, et al. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis. J Infect Dis 1998; 177: 668-676.
31. Carr C, et al. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 1994; 44: 126-137.
32. Creasey AA, et al. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-2860.
33. de Jonge E, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-1129.
34. Moons AH, et al. Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees. Thromb Haemost 2002; 88: 627-631.
35. Abraham E, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. J Am Med Assoc 2003; 290: 238-247.
36. Bastarache JA, et al. The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax 2007; 62: 608-616.
37. Choi G, et al. Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection. Eur Respir J 2004; 24: 786-789.
38. Enkhbaatar P, et al. Recombinant tissue factor pathway inhibitor prevents lipopolysaccharide- induced systemic hypotension in rats by inhibiting excessive production of nitric oxide. Thromb Haemost 2001; 86: 1573-1577.
39. Schultz MJ, et al. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004; 59: 130-135.
40. Hoogerwerf JJ, et al. Activation of coagulation and inhibition of fibrinolysis in the human lung on bronchial instillation of lipoteichoic acid and lipopolysaccharide. Crit Care Med 2009; 37: 619-625.
41. Bajaj MS, et al. Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost 1999; 82: 1047-1052.
42. Maroney SA, et al. Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. Proc Natl Acad Sci USA 2012; 109: 3927-3931.
43. Singh R, et al. Tissue factor pathway inhibitor deficiency enhances neointimal proliferation and formation in a murine model of vascular remodelling. Thromb Haemost 2003; 89: 747-751.
44. Rothmeier AS, Ruf W. Protease-activated receptor 2 signaling in inflammation. Semin Immunopathol 2012; 34: 133-149.
45. Shpacovitch V, et al. Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J Leukoc Biol 2008; 83: 1309-1322.
46. Taylor FB, Jr., et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-134.
47. Ahamed J, et al. Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1. Blood 2005; 105: 2384-2391.
48. Sun H, et al. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 2009; 113: 1358-1364.
49. Loof TG, et al. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood 2011; 118: 2589-2598.
50. Papareddy P, et al. The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis. PLoS Pathog 2013; 9: e1003803.